Retreatment Strategies for Patients Failing First-Line Therapy
Source: Advanced Topics in Hepatitis C Management: Tools for Nurse Practitioners and Physician Assistants


HoChong Gilles, RN, MS, FNP, reviews clinical management options for patients with chronic HCV infection who fail interferon-based therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify causes of nonresponse and relapse to hepatitis C virus (HCV) therapy
  • Describe definitions of response during HCV therapy and key time points for monitoring response to treatment
  • Discuss diagnosis and management of common adverse effects of HCV therapy and strategies for monitoring patient adherence
  • Recall strategies for selecting optimal treatment for patients based on their baseline factors and previous course of therapy

Topics covered include:

  • Introduction
  • Treatment Response Patterns
  • Factors Contributing to Treatment Failure
  • Comorbidities as Predictors of Nonresponse
  • Other Factors Associated With Nonresponse
  • Assessing Factors Related to Nonresponse Before Retreatment
  • Retreatment Options in Nonresponders and Relapsers
  • Summary: Implications for Clinical Practice

Program Directors

  • Michael W. Fried


  • HoChong Gilles
    RN, MS, FNP

Credit Information

  • Release Date:
    June 28, 2007
  • Expiration Date:
    June 27, 2008
  • Physicians:
    maximum of 1.5 AMA PRA Category 1 Credits
  • Registered Nurses:
    1.5 Nursing contact hours
  • Physician Assistants:
    maximum of 1.5 hours of AAPA Category I (Preapproved) credits
  • My Take on New Guidance for Treating Genotype 1 HCV–Infected Patients With Decompensated Cirrhosis

    Norah Terrault MD, MPH - 5/5/2015    3 comments / Last Comment: 7/26/2015
    We now have safe and effective treatment options for HCV infection in patients with decompensated cirrhosis. But how do ribavirin tolerability and treatment experience factor into how they should be used?
  • My Evolving Strategy for Treating Patients With Genotype 3 HCV Infection

    Norah Terrault MD, MPH - 9/10/2015    2 comments / Last Comment: 10/3/2015
    Following the recent FDA approval of daclatasvir and the presentation of key data at the 2015 EASL meeting, our team has made several changes to our approach in managing patients with genotype 3 HCV infection.
  • How I Expect Evolving Options for HCV Therapy Will Affect Posttransplant Management

    Paul Y. Kwo MD - 7/29/2015    
    Will we finally have options to prevent posttransplantation HCV recurrence across the spectrum of genotypes?
  • Patients With Renal Disease: One of the Remaining Challenges in HCV Therapy

    Nancy Reau MD - 8/25/2015    
    A recent patient discussion highlighted important questions about how to approach HCV infection in renal disease.
  • Post-EASL Update: Is It Time to Use Resistance Testing to Guide HCV Treatment Decisions?

    Jordan J. Feld MD, MPH - 7/28/2015    1 comment / Last Comment: 8/7/2015
    With the highly effective DAA regimens now available for treating patients with HCV, fewer patients experience treatment failure. Could pretreatment-resistance testing help to decrease failures even further?